Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carci… Read more
Biofrontera AG (B8FK) - Total Liabilities
Latest total liabilities as of September 2025: €5.01 Million EUR
Based on the latest financial reports, Biofrontera AG (B8FK) has total liabilities worth €5.01 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biofrontera AG - Total Liabilities Trend (2009–2024)
This chart illustrates how Biofrontera AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biofrontera AG Competitors by Total Liabilities
The table below lists competitors of Biofrontera AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Friday's Dog Holdings Inc.
PINK:FDOGF
|
USA | $595.93K |
|
Indian Card Clothing Company Limited
NSE:INDIANCARD
|
India | ₹288.15 Million |
|
R. S. Software (India) Limited
NSE:RSSOFTWARE
|
India | ₹299.15 Million |
|
Baselode Energy Corp
OTCQB:BSENF
|
USA | $5.71 Million |
|
Alumexx N.V.
AS:ALX
|
Netherlands | €30.87 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
Australia | AU$2.36 Million |
|
mVISE AG
XETRA:C1V
|
Germany | €6.96 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Biofrontera AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biofrontera AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biofrontera AG (2009–2024)
The table below shows the annual total liabilities of Biofrontera AG from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €10.80 Million | +0.43% |
| 2023-12-31 | €10.75 Million | -13.21% |
| 2022-12-31 | €12.39 Million | -33.75% |
| 2021-12-31 | €18.70 Million | -61.85% |
| 2020-12-31 | €49.02 Million | +1.26% |
| 2019-12-31 | €48.41 Million | +112.53% |
| 2018-12-31 | €22.78 Million | +38.32% |
| 2017-12-31 | €16.47 Million | +104.90% |
| 2016-12-31 | €8.04 Million | -43.83% |
| 2015-12-31 | €14.31 Million | +1.96% |
| 2014-12-31 | €14.03 Million | -1.08% |
| 2013-12-31 | €14.18 Million | +8.04% |
| 2012-12-31 | €13.13 Million | -27.97% |
| 2011-12-31 | €18.23 Million | +17.90% |
| 2010-12-31 | €15.46 Million | +12.56% |
| 2009-12-31 | €13.74 Million | -- |